Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
AssigneeAlexion Pharmaceuticals, Inc.
InventorsAndrew DENKER, Rajendra PRADHAN, Douglas L. SHERIDAN, Marc VALLEE, Yang DAI, Xiang GAO
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods for treating a human patient with a complement-associated condition (e.g., PNH or aHUS) by subcutaneously co-administering to the patient a hyaluronidase (e.g., rHuPH20) and an anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab).
Claims22
A method of treating a human patient with a complement-associated condition, the method comprising subcutaneously co-administering to the patient a hyaluronidase and an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, comprises CDR1, CDR2, and CDR3 heavy chain sequences as set forth in SEQ ID NOs:
- 19, 18, and 3, respectively, and CDR1, CDR2, and CDR3 light chain sequences as set forth in SEQ ID NOs:
- 4, 5, and 6, respectively.
-16. (canceled)
-31. (canceled)
-34. (canceled)
-38. (canceled)
Dependencies are inferred from the claim text.